CTI BioPharma (CTIC) Misses Q2 EPS by 9c

August 6, 2015 4:55 PM

CTI BioPharma (NASDAQ: CTIC) reported Q2 EPS of ($0.19), $0.09 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $1.1 million, versus $1.3 million reported last year.

For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.



Next Articles